Overview

• Published in Frontiers in Science, the review from Brigham and Women's Hospital and Harvard researchers consolidates AI, multi-omics and systems biology as a unified framework for cardiovascular drug discovery.
• The authors argue these tools can pinpoint individualized targets, enable digital drug design and open previously "undruggable" pathways, potentially cutting development time, costs and failure rates.
• RNA-based medicines are highlighted as a strategic avenue, with early trials indicating stronger cholesterol lowering than some standard therapies and rapid design against gene targets.
• The paper underscores urgency by projecting cardiovascular deaths rising from about 19 million in 2020 to roughly 26 million annually by 2030.
• The team calls for coordinated policy leadership, substantial funding, open-science practices and collaborations across academia, industry and healthcare, with a Frontiers multimedia hub and a Nov. 17 webinar set to advance the conversation.